Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS

\- INCLUSION CRITERIA: PATIENT

* Ages 50-75 years
* Relapsed CML in chronic or accelerated phase after therapy with STI-571 (Gleevec)
* Acute lymphoblastic leukemia (ALL), all patients in complete or partial remission. Exceptions: T cell ALL
* Acute myelogenous leukemia (AML): AML in first complete or partial remission including AML secondary to chemotherapy or prior hematological disease such as myelodysplastic syndrome, and myeloproliferative disorder.
* Myelodysplastic syndromes: (1) refractory anemia with excess of blasts (RAEB), (2) refractory anemia with excess blasts in transformation (RAEBT), (3) MDS with poor risk cytogenetics defined by a complex karyotype (greater than or equal to three anomalies) or chromosome 7 abnormalities, (4) secondary MDS after prior cytotoxic or radiation therapy, or (5) chronic myelomonocytic leukemia (CMML)
* Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia, refractory to nucleoside analog therapy, with either progressive bulky disease or anemia (less than 10 g/dl) or thrombocytopenia (less than 100,000/microliter) not due to recent chemotherapy
* Mantle cell lymphoma
* Relapsed intermediate- or high-grade non-Hodgkin's lymphoma: (1) post autologous marrow or PBSC transplant, or (2) chemorefractory relapse. Exceptions: T cell NHL
* Relapse Hodgkin's disease: (1) post autologous marrow or PBSC transplant, or (2) chemorefractory relapse
* Low-grade follicular or small lymphocytic lymphoma: (1) relapsed following conventional chemotherapy, (2) relapsed following autologous marrow or PBSC transplant, or (3) chemoresistant disease
* Life expectancy greater than 3 months
* Ability to comprehend the investigational nature of the study and provide informed consent
* Availability of an HLA-identical family donor, 18 to 75 years old
* INCLUSION CRITERIA:

DONOR

* HLA identical family donor, 18 to 75 years old
* Fit to receive G-CSF and give peripheral blood stem cells (normal blood count, normotensive, no history of stroke, no history of severe heart disease)
* Ability to comprehend the investigational nature of the study and provide informed consent
* EXCLUSION CRITERIA:

RECIPIENT

* Pregnant or lactating
* Eastern Cooperative Oncology Group (ECOG) performance status of 3 or more
* Major anticipated illness or organ failure incompatible with survival from PBSC transplant
* Diffusion Capacity fir carbon monoxide (DLCO) less than 60% predicted
* Left ventricular ejection fraction less than 40%, or any angina.
* Absolute lymphocyte count less than 300/mm(3)
* Serum creatinine greater than 2.5 mg/dl
* Serum bilirubin greater than 4 mg/dl, transaminases greater than 5x upper limit of normal
* HIV positive
* Other malignant diseases liable to relapse or progress within 2 years
* EXCLUSION CRITERIA:

DONOR

* Pregnant or lactating
* HIV positive. Donors who are positive for Hepatitis B Virus, Hepatitis C Virus or human t-cell lymphoma virus (HTLV) will be used at the discretion of the investigator and with appropriate consent of the recipient
* Donor unfit to receive G-CSF and undergo apheresis (uncontrolled hypertension, history of heart failure or unstable angina, platelet count less than 90,000/cu mm)